Eyeworld Daily News

70 | EYEWORLD DAILY NEWS | MAY 4, 2019 ONSITE ASCRS ASOA ANNUAL MEETING Seventh annual Run for Sight tomorrow morning The symposium will conclude with a panel discussion on evolv- ing reimbursement models for these new technologies, including pass-through status, and the im- pact of reimbursement pathways on patient access to technology to control pain and inflammation. The 1-hour symposium will take place in ballroom 20D. Registration and a reception will begin at 5:00 p.m., with the edu- cational program running from 5:30 to 6:30 p.m. This program is supported by educational grants from EyePoint Pharmaceuticals, ImprimisRx, Ocular Therapeutix, and Omeros. T his evening, Eric Don- nenfeld, MD, and Edward Holland, MD, will co-moderate an EyeWorld CME Educa- tion event on "Improv- ing the Cataract Patient Experience: Minimizing Pain and Inflammation while Reducing the Need for Topical Drops." The faculty includes Alice Epitropoulos, MD, Denise Visco, MD, and William Wiley, MD. Dr. Holland will address the impact of pain and inflammation on cataract surgery patient per- ceptions of the procedure and the surgeon. "The reality is that pa- tients can sometimes be unhappy even with a 20/20 visual outcome if their pain is not managed well during the procedure," he said. Nearly 90% of respondents to the 2018 ASCRS Clinical Survey agreed or strongly agreed that intraocular inflammation after cat- aract surgery can significantly af- fect visual quality, vision recovery time, and patient satisfaction. Dr. Holland will also discuss who is at higher risk for inflammation, who is non-adherent with prescribed drop regimens, and why those factors should be taken into con- sideration. Currently, topical drops preoperatively and/or postopera- tively are the most common way to address inflammation arising from cataract surgery. Nearly 50% of the survey respondents said they dose NSAIDs for 4 weeks postop, and 76% dose steroids for 4 weeks postop. Forty to 55% of survey respondents either begin anti-inflammatory drops preop or prescribe them for a longer dura- tion in higher-risk patients. Each faculty member will then give a 5-minute overview on intraoperative strategies to better control pain and inflammation while reducing the number and duration of topical drops. Key strategies to be addressed include intracameral dexamethasone, punctal plug extended release delivery of dexamethasone, nano- technology loteprednol, intracam- eral ketorolac/phenylephrine, and the use of compounded combina- tion medications. At present, only 27% of ASCRS Clinical Survey respondents rely on any form of intraoperative instillation of anti- inflammatory agents, but more than one-third are considering using these new approaches. Tonight: EyeWorld CME Education event on improving the cataract patient experience T he seventh annual ASCRS Foundation Run for Sight will take place tomorrow morning along the San Diego harbor. The race is sponsored by John- son & Johnson Vision. Last year, nearly 400 people participated in the Run for Sight, and the event is back in San Diego for the first time since 2015. The 5K race will begin at 6:30 a.m., with welcoming remarks, an aerobic warm-up, and a group photo prior to the start time. There will also be a 1-mile walk. Those who would like to participate can register onsite at the meeting or at the race on Sunday morning. "The Run for Sight is a wonderful way to join friends and colleagues for some fun and exercise while at the ASCRS ASOA Annual Meeting," said Don Bell, executive director of the ASCRS Foundation. "Thanks to the generous support of Johnson & Johnson Vision, all money raised through the run goes directly to help fund the ASCRS Foundation's charitable cataract surgery programs, both here in the United States and in Ethio- pia. We look forward to a big crowd, warm weather, and an enjoyable run along the San Diego harbor front." The 2018 Run for Sight in Washington, D.C. Source: ASCRS

• Blank Page
• Blank Page (1)